Comparison of Chemotherapy Effects on Mechanical Sensitivity and Food-Maintained Operant Responding in Male and Female Rats
L. P. Legakis, C. M. Diester, E. A. Townsend, L. Karim-Nejad, S. S. Negus
Abstract
ObjectiveChemotherapies of varying classes often cause neuropathy and debilitating chemotherapy-induced neuropathic pain (CINP) sufficient to limit treatment and reduce quality of life for many patients battling cancer. There are currently no effective preventative or alleviative treatments for CINP. Preclinical models have been developed to test candidate CINP treatments; however, studies using these models rarely provide direct comparisons of effects of different chemotherapies or assess the degree to which chemotherapies produce clinically relevant signs of pain-depressed behavior.\n\nMethodsMale and female Sprague-Dawley rats received four injections of vehicle, paclitaxel, oxaliplatin, vincristine, or bortezomib on alternate days. Mechanical hypersensitivity, body weight, and food-maintained operant responding were evaluated before, during, and for up to 42 days after initiation of treatment. Morphine potency and effectiveness to reverse chemotherapy-induced effects were also evaluated.\n\nResultsAll four chemotherapies produced dose-dependent and sustained mechanical hypersensitivity in all rats. Vincristine and oxaliplatin produced transient weight loss and decreases in food-maintained operant responding in all rats, whereas paclitaxel and bortezomib produced lesser or no effect. At four weeks after treatment, operant responding was depressed only in paclitaxel-treated males. Morphine reversed mechanical hypersensitivity in all rats but failed to reverse paclitaxel-induced depression of operant responding in males.\n\nConclusionsChemotherapy treatments sufficient to produce sustained mechanical hypersensitivity failed to produce sustained or morphine-reversible behavioral depression in rats. Insofar as pain-related behavioral depression is a cardinal sign of CINP in humans, these results challenge the presumption that these chemotherapy-dosing regimens are sufficient to model clinically relevant CINP in rats.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice
Laura R. Osborn, Mary Grace Bishop, … Kimberly Stephens·Current NeuropharmacologyPeer-reviewed·Apr 21, 2026
- Meteorin alleviates Paclitaxel-induced peripheral neuropathy in mice
Ishwarya Sankaranarayanan, Diana Tavares‐Ferreira, … Theodore John Price·bioRxiv·Sep 13, 2022
- Effects of gabapentin on ongoing behaviors displayed by mice with chemotherapy neuropathy
Bradey A. R. Stuart, Bhavya S. Dharanikota, Cheryl L. Stucky·bioRxiv·Jul 1, 2026
- Meclizine and metabotropic glutamate receptor agonists attenuate severe pain and primary sensory neuron Ca2+ activity in chemotherapy-induced peripheral neuropathy
John L. Shannonhouse, Matteo Bernabucci, … Yu Shin Kim·Journal of NeurosciencePeer-reviewed·Jun 30, 2022
- Neuroinflammation induces nerve growth factor dependent nociceptor sensitisation in a neonatal rodent model of platinum-based chemotherapy induced neuropathic pain
Marlene E. Da Vitoria Lobo, Lydia D. Hardowar, … Richard P. Hulse·Disease Models & MechanismsPeer-reviewed·Oct 21, 2024
- Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis A comprehensive summary of the field to inform robust experimental design
Gillian L. Currie, Helena N. Angel-Scott, … Emily S. Sena·PLoS BiologyPeer-reviewed·May 20, 2019